Pathos
Pathos develops an AI-enabled drug discovery platform aimed at reducing the medication development process. Its self-learning platform uses big data, technology, and artificial intelligence to identify targets, validate them, and establish their clinical efficacy, enabling drug developers to explore novel concepts and advance breakthrough therapies for various diseases.
Top Stages
1 past transactions
Rain Oncology
Acquisition in 2023
Rain Oncology Inc. is a late-stage precision oncology company focused on developing targeted therapies aimed at oncogenic drivers. The company employs a genetic selection strategy to identify patients who are most likely to benefit from its treatments, utilizing a tumor-agnostic approach that prioritizes the underlying genetics of tumors over traditional histological classifications. Its lead product candidate, milademetan, is a small molecule oral inhibitor of MDM2, which plays a role in various cancers. Additionally, Rain Oncology is advancing a preclinical program aimed at inducing synthetic lethality in cancer cells by inhibiting RAD52, further diversifying its therapeutic pipeline.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.